Experimental drug aims to tame rare nerve disorder
NCT ID NCT07696377
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This trial tests a drug called obinutuzumab β in people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a condition where the immune system attacks nerves, causing weakness and numbness. Participants receive two intravenous infusions of the drug and are monitored for about 73 weeks to see if it reduces relapses. The goal is to find a safer and more effective way to control this rare nerve disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- obinutuzumab β
- What this could lead to
- If successful, this could provide a new treatment option for people with CIDP, potentially reducing relapses and the need for rescue therapies.
- What could go wrong
- This is a small, early-phase trial (Phase 1/2) with only 24 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for teens with rare nerve disease: drug trial launches
- New hope for CIDP: modified immune protein enters human testing
- New immune globulin drug shows promise for rare nerve diseases in japan
- CIDP patients switching to HyQvia: what drives the choice?
- New shot for nerve disease could mean fewer infusions